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Abstract 
Retinoblastoma is a rare cancer of the infant retina, which forms when both RB1 alleles mutate in a susceptible 
retinal cell, likely a cone photoreceptor precursor. Loss of the tumour suppressor functions of the retinoblastoma 
protein, pRB, leads to uncontrolled cell division and recurrent genomic changes during tumour progression. 
Although pRB is expressed in virtually all tissues, cone precursors have biochemical and molecular features that 
may sensitize to RB1 loss to enable tumourigenesis. Retinoblastoma is diagnosed in ~8,000 children each year 
worldwide. Patient survival is >95% in high-income countries, but <30% globally. However, outcomes are 
improving through increasing awareness for earlier diagnosis, new guidelines and sharing of expertise. Intra-
arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes. Ongoing 
international collaborations will replace the multiple different classifications of eye involvement with 
standardized definitions to consistently assess eligibility, efficacy and safety of treatment options. Life-long 
follow-up is warranted since survivors of heritable retinoblastoma are at risk for developing second cancers. 
Defining the molecular consequences of RB1 loss in diverse tissues may open new avenues for treatment and 
prevention of retinoblastoma as well as second cancers in patients with germline RB1 mutations.  
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[H1] Introduction  
Retinoblastoma is a rare cancer usually initiated by biallelic mutation of the retinoblastoma gene (RB1) in a 
single susceptible developing retinal cell. Inheritance of one mutant RB1 allele strongly predisposes to 
retinoblastoma tumours that form after the second RB1 allele is mutated.1 The principles discovered by studying 
retinoblastomas have led to the recognition that inactivation of tumor suppressor genes broadly contributes to 
human tumorigenesis. 
Retinoblastoma initiates after an RB1-/- retinal cell undergoes limited proliferation to form a non-malignant 
retinoma (Figure 1)2 An intraretinal tumour develops after genetic or epigenetic changes lead to uncontrolled 
proliferation. Most commonly, this is first detected when the white tumour is visible through the pupil 
(leukocoria) or blocks vision.3 When noticed early, prompt treatment can cure the cancer and save the eye(s). 
However, delayed diagnosis can lead to incurable invasion of the optic nerve and brain, or to metastases 
elsewhere in the body that are sometimes cured by extensive intervention. 
Several questions related to our understanding of retinoblastoma and its optimal clinical management remain. 
The cell of origin of retinoblastoma has been difficult to pinpoint; new research we review in this Primer has 
potential to improve our understanding of why the infant retina is uniquely predisposed to malignancy upon RB1 
loss. The evidence base for clinical management is weak. Rigorous randomized clinical trials (RCTs) in 
retinoblastoma are missing for multiple reasons: too few patients in countries with capacity to conduct clinical 
trials; often complex presentation (two eyes with differing severity); too few patients to interest the 
pharmaceutical industry; often-opposing schools of thought and difficulties in transdisciplinary collaborations; 
and high societal value on eyes and vision imposes considerations beyond curing the cancer. New technologies 
showing dramatic tumour responses have been quickly embraced, without rigorous clinical science. Differences 
in resource availability, medical expertise, and societal and health system structure vary between and within 
nations, making recommendations for optimal care complex and context-dependent. 
To address these challenges, this Primer on retinoblastoma introduces unprecedented new science, ideas, 
therapies and global collaboration. The Internet has opened many avenues: parents diagnose retinoblastoma 
themselves; colleagues share patients around the globe; centres of excellence are mapped; and a common 
database for all children — no matter where they live — is within reach. These developments are set to 
empower a ‘learning health system’ that will build the evidence base to optimise care.  
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[H1] Epidemiology  
[H2] Global incidence and outcomes  
The expected number of patients with retinoblastoma annually per country is most accurately calculated by 
multiplying the global retinoblastoma incidence (1 in 16,000–18,000 live births) by number of forecast 
surviving infants (birth rate minus infant mortality rate) (Table 1).4-6 Using these formulas, approximately 8,000 
new cases are predicted each year. The number of children predicted in each country are indicated in 
Supplementary Table 1. Calculations as in Table 1 accurately predict retinoblastoma in many countries.7-9 There 
is no validated evidence of geographical or racial variations of retinoblastoma incidence.6,10,11 
Of all affected children, 11% reside in high-income, 69% in middle-income and 20% in low-income countries.12 
Although prevalence is higher in middle- to low-income countries (Figure 2), most retinoblastoma treatment 
centres are in middle- and high-income countries, creating a gap in healthcare access (Table 2). Consistent with 
income being a surrogate for non-economic measures of standard of living, retinoblastoma in low-income 
countries is associated with low patient survival (~30%13,14) compared with high-income countries (>95%8), but 
comprehensive nation-wide data are lacking.  
Poor outcome correlates with late diagnosis, difficulty accessing retinoblastoma-specific health care, and socio-
economic issues leading to poor compliance, including family refusal to remove the affected eye (enucleation) 
and abandonment of therapy.11,15,16 Without timely diagnosis and appropriate treatment, difficult-to-cure 
metastatic disease may develop. Fortunately, with early diagnosis,17 many eyes can be safely treated and support 
a lifetime of good vision, pointing to key elements for global focus: awareness, collaboration, and affordable 
expert care.  
[H2] Solutions for global retinoblastoma 
A number of initiatives address the inequality in retinoblastoma treatment between developing and developed 
countries. In 2009, the Canadian National Retinoblastoma Strategy (NRbS) published the first-ever 
retinoblastoma clinical practice guidelines,8 adapted by the Kenyan National Retinoblastoma Strategy (KNRbS) 
and published in 2014 in partnership with the Kenyan Ministry of Health.18 The KNRbS has supported the 
standardization of histopathologic examination of the enucleated eye to inform treatment decisions and 
discussion of prognosis with families. Adoption of upfront (first-line) enucleation with implants and immediate 
prosthetic eyes19 (sourced from India), parent-to-parent interactions to allay uninformed fears, and 
standardization of information provided to parents has reduced the rate of non-compliance with treatment.18,20 In 
2013, the Paediatric Oncology in Developing Countries Committee of the SIOP (International Society of 
Paediatric Oncology) published a consensus guideline for the management of retinoblastoma in countries with 
limited resources21 with clear ideas that can shape resource development. The Mexican National Strategy22 and 
the Brazilian SOBOPE (Brazilian Society of Paediatric Oncology)23 guidelines are also applicable at a national 
level with governmental support for treatment.  
Peer-to-peer collaborations and twinning programmes have built a framework for knowledge and expertise 
exchange, filling gaps in specialized training, and donating equipment and resources with the ultimate aim to 
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ensure sustainable local capacity to deliver optimal health care.24 Retinoblastoma-specific twinning programmes 
include partnerships between St. Jude’s Children’s Research Hospital (USA) and the Middle-East,25 Central 
America26 and Mexico,22and between the Institut Curie and a centre in Bamako, Mali.27 The Central American 
Association of Paediatric Hematology Oncology (AHOPCA) created a cooperative group and implemented 
multicentre protocols for retinoblastoma treatment,26,28,29 a major achievement, not yet paralleled in developed 
countries. The AHOPCA funding is now 90% local. Twinning programmes benefit from strong participation of 
both governmental and non-governmental organizations (NGO). However, where government may prove 
volatile and unpredictable, sustainable local capacity is a challenge. Less formal cooperation between developed 
and less developed countries can also result in highly efficient programmes.30,31 
A successful national strategy has been developed in China. About 1,100 newly diagnosed cases are forecast 
annually, scattered over 32 provinces. Before 2005, enucleation was the only available treatment for most 
children. For better treatment options and follow-up, centres classified by expertise and resources were 
established in 28 hospitals covering 25 provinces (over 90% of the population), which profoundly reduced travel 
costs12. The improved efficiency and national collaboration from 2006 to 2014 has led to standardized 
classification and treatment of 2,097 newly diagnosed patients with retinoblastoma on common protocols, which 
has led to increased survival (unpublished data, J.Z.). In Argentina, a single centre with high expertise 
coordinates affiliated retinoblastoma clinics. This collaboration between governmental hospitals, local and 
international NGOs with prospective protocols has significantly improved survival in two decades, in addition to 
stimulating translational research and population-based incidence and survival studies.32 33,34 
In a rapidly changing world, online strategies are facilitating global collaboration. The One Retinoblastoma 
World initiative (www.1rbw.org) leads families to the nearest centre with known expertise.12 The 
retinoblastoma-specific point-of-care database (eCancerCareRB, eCCRB) summarizes the medical record for 
retinoblastoma for each affected child. eCCRB is freely accessible online to every retinoblastoma centre with 
local ethics and privacy approvals. The Disease-specific, electronic Patient Illustrated Clinical Timeline 
(DePICT) is language-independent, is understandable by parents, and supports fully informed care choices.35 
With guardian consent, identifiable data is accessible to those in the circle of care of each child. Ultimately, the 
de-identified data will be fuel for powering a global learning health system for retinoblastoma.  
[H1] Mechanisms/pathophysiology  
[H2] Genetic basis of retinoblastoma  
The search for the genetic basis of retinoblastoma provided the two-hit model of tumour suppressor gene 
inactivation. In 1971, Knudson discovered that the ages of retinoblastoma diagnosis are consistent with one rate-
limiting event in bilaterally affected patients (who have heritable disease) (median age at diagnosis 12 months), 
and with two rate-limiting events in unilaterally affected patients with no family history (who usually have the 
non-heritable form) (median age at diagnosis 24 months).36 This prompted the proposal that heritable 
retinoblastomas result from a germline mutation (‘first hit’, M1) and an acquired somatic mutation (‘second hit’, 
M2), whereas non-heritable retinoblastomas arise when two somatic mutations are present in the same 
transformation suppressor gene in a susceptible cell (Figure 3).37 Chromosomal deletions in some patients 
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pointed to a chromosome (chr.) 13q14 locus. Loss of heterozygosity of chr. 13q14 polymorphic markers in 70% 
of retinoblastoma tumours38 implied that the second hit involved the same locus. The breakthrough came when 
one retinoblastoma was found to be missing the sequence of a chr. 13q DNA clone,39 that was shown to be a 
conserved exon sequence of RB1.39-42 Although RB1 loss consistently initiates cancer in the retina, RB1 function 
can be lost with progression in almost all cancer types.43 
RB1 is a large (190 kb) gene with 27 exons, encoding a 4.7 kb mRNA that translates into a 928 amino acid 
protein, pRB. Many modifications impair pRB function, including point mutations, promoter methylation, and 
small and large deletions.44 Even chromothripsis, a “shattering” of a genomic region resulting in widespread 
rearrangements, has been shown to underlie a minority of cases.45 The A/B “pocket” region46 harbours most 
missense mutations.  
pRB is best known as a cell cycle regulator that binds to E2F transcription factors to repress cell proliferation-
related genes. Hyperphosphorylation of pRB by cyclin-dependent kinases (CDKs) in response to mitogenic 
signals normally relieves repression and promotes the G1 to S phase transition. pRB loss relieves this repression 
in the absence of mitogenic signals to enable cell cycle entry. It is tempting to surmise that pRB is primarily 
needed to suppress E2F transcription factors, and that loss of this function is the main cause of retinoblastoma 
formation.46 However, several “low penetrance” RB1 mutations encode proteins with minimal ability to bind 
E2F but unexpectedly these mutations predispose to far fewer tumours than RB1 null alleles.47,48 Thus, such 
defective E2F-binding alleles may function to substantially block retinoblastoma development through one or 
more of pRB’s E2F-independent functions.46 For example, pRB also up-regulates p27, and this effect has been 
implicated in cell differentiation, apoptosis, and genomic integrity.46 However, during cone precursor 
maturation increasing pRB is associated with decreasing p27 expression,49 arguing that p27 would not mediate 
retinoblastoma suppression in these cells.49 The loss of pRB N-terminus functions such as non-homologous end-
joining may also be important but are not clearly implicated in retinoblastoma initiation.50,51 Thus, the exact 
mechanism by which pRB normally suppresses retinoblastoma remains to be identified.  
Biallelic RB1 inactivation is necessary to initiate most retinoblastomas, but is not sufficient, since the benign 
retinal lesion, retinoma, has lost both RB1-/- alleles (Figures 1 and 3).2 Further genetic or epigenetic changes are 
likely needed for malignant transformation.52 Epigenetic alterations might drive retinoblastoma formation by 
inducing H3K4 trimethylation and H3K9 and H3K14 acetylation marks and expression of the SYK oncogene.53 
Comparative genomic hybridization studies identified DNA copy number gains encompassing the candidate 
retinoblastoma oncogenes mitotic kinesin KIF14 and the p53 regulator MDM4 (chr. 1q32), transcription factors 
E2F3 and DEK (chr. 6p22), and the onco-miR clusters miR-106b~25 (chr. 7q22.1) and miR-17~92 (chr. 13q31, 
as well as losses encompassing the cadherin-11 (CDH11) (chr. 16q22) and pRB family member RBL2 (chr. 
16q12.2) tumour suppressor genes.52 Whole-genome sequencing identified inactivating mutations in the 
transcriptional corepressor BCOR encoding the BCL-6 corepressor.53 Interestingly, some tumors had no 
detected alterations,53 consistent with acquisition of such changes during tumour progression.54  
Many other genes and microRNAs also show altered expression in retinoblastoma compared to normal retina.52 
Gene expression profiles were initially proposed to reveal only a single relatively homogeneous class of 
retinoblastoma55 and were subsequently proposed to segregate RB1-/- retinoblastomas into two subtypes.56 
However, analyses of a larger cohort recently revealed a spectrum of phenotypes reflecting progression from a 
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state with high photoreceptor differentiation and few cytogenetic changes to a state with lower differentiation, 
increased mRNA and ribosome biogenesis and mitosis gene expression signatures, and increased cytogenetic 
aberrations.54 Thus, RB1-/- retinoblastomas appear to progress from self-limiting retinomas to differentiated 
retinoblastoma to less differentiated malignancies. 
Whereas both RB1 alleles are mutated in nearly all retinoblastomas, a subset of unilateral tumours (1.4%) show 
no evidence of RB1 mutation but have high-level amplification of the oncogene MYCN (amplified MYCN, 
MYCNA).57 These RB1+/+MYCNA tumours are always unilateral, are diagnosed in much younger children than 
unilateral RB1-/- tumours, and have a distinct morphology, reflecting a unique subtype. Although they also fall 
within the photoreceptor differentiation and mitosis/RNA biogenesis spectrum of RB-/- tumours, RB1+/+MYCNA 
tumors are distinct outliers in levels of expression of many genes,54 consistent with the idea that they originate in 
a earlier retinal precursor.57 Another 1.5% of unilateral non-familial retinoblastomas are unexplained and have 
apparently normal RB1 and MYCN genes.57  
 [H2] The retinoblastoma cell of origin 
Since RB is expressed in most if not all cells, the retina’s unique sensitivity to RB loss has been perplexing. 
While the key to this sensitivity likely relates to the features of the cell of origin, the identity of this cell has 
been elusive.  Studies addressing the cell of origin through analysis of tumours offered puzzling clues, as the 
tumours expressed diverse retinal cell type markers. Together with other evidence, the diverse cell marker 
expression suggested either a pluripotent cell of origin, aberrant co-expression of marker genes due to oncogenic 
transformation, or the presence of normal RB1+/+ retinal cells within largely cone-like tumours.55,58 Mouse 
models have not clarified the cell-of-origin, since such models have required an additional mutation of Rbl1, 
Rbl2, or Cdkn1b on top of Rb1 loss,59 and the resulting tumours express a different spectrum of retinal markers, 
raising the possibility that they might not extrapolate to humans.60 
A clue to the cell of origin came from the finding that the topographic distribution of emerging retinoblastomas 
mimics the horizontal visual streak characteristic of red and green cones, which provided evidence that the 
tumours could derive from a cell in the cone photoreceptor lineage.48 Consistent with this view, RB1-/- 
retinoblastomas consistently express cone photoreceptor markers but not other retinal cell type-specific proteins. 
In addition, normal post-mitotic maturing cone precursors have unusually high expression of pRB as well as 
oncoproteins (MDM2 and MYCN) that could collaborate with RB1 loss to enable cone precursor proliferation 
(Figure 4a, b).46,61 More recently it was shown that experimental depletion of RB1 induces human cone 
precursor cell proliferation in vitro and pRB-depleted human cone precursors form tumours typical of 
differentiated retinoblastomas in orthotopic xenografts.62 The proliferation of these normally post-mitotic cells 
depends upon their intrinsically high levels of MYCN and MDM2, cone-specific transcription factors RXRγ and 
TRβ2, and down-regulation of p27, which is associated with normal cone precursor maturation.49,62 Thus, pRB 
may counter an oncogenic programme associated with cone precursor maturation.  
Notably, the smallest tumours detected via optical coherence tomography (OCT) appear to be centered in the 
inner nuclear layer (INL) of the retina, not the outer nuclear layer (ONL) where mature cones reside (Figure 
4c).63 Possibly, the cone precursor cell that loses pRB mislocalizes to the INL. However, as they grow, the small 
tumors also extend into ONL and other retinal layers (Figure 4c), making it difficult to infer the retinal layer in 
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which tumors first form. Perhaps blood vessels and retinal astrocytes that are normally present in the inner retina 
promote retinoblastoma cell growth in the INL.64 
 [H2] Translating knowledge of pathogenesis  
Understanding retinoblastoma molecular pathways could lead to treatment and prevention opportunities. 
Oncoproteins such as MYCN could be targeted65 in both RB1+/+MYCNA tumours57 and RB1-/- tumours that have 
MYCN-dependence.61 Furthermore, studies based on molecular discoveries showed that exposing 
retinoblastoma-prone murine foetuses to small molecule inhibitors of E2f or Cdk inhibited subsequent 
tumourigenesis without disrupting normal retinal development.59 
These new translational opportunities require cell lines and animal models that accurately reflect retinoblastoma 
cell responses. Most in vitro studies have used two old cell lines, but many others are available.66 Primary 
xenografts in newborn rats and immunodeficient mice67 are useful53 but will not reflect the cell and immune 
environment of natural retinoblastoma, potentially limiting translation to patients. Genetically engineered mouse 
models can also be used to assess novel treatments.68 Whereas Rb1+/- mice (which are expected to lose the wild 
type Rb1 allele as in RB1+/- humans) do not develop retinoblastoma, retinal-specific deletion of both alleles of 
Rb1 (using Pax6a, Nes (Nestin), or Chx10 promoters) in Rbl1, Rbl2 or Cdkn1b deficient backgrounds achieves 
retinal tumour formation.60 Models such as overexpression microRNA cluster miR-17~92 have been used to 
examine genetic interactions in vivo.69 Mice expressing the viral oncoprotein Simian Virus 40 large T-antigen 
develop retinoblastoma specifically in precursors of Müller cells (a type of retinal glia cells), and have been 
used extensively for pre-clinical therapeutic studies.70,71 However, experimental murine tumours have different 
collaborating mutations and cell type origin, reducing their ability to predict human treatment responses. New 
models that more precisely recapitulate human retinoblastoma pathogenesis are needed to identify novel 
therapies that will target RB1-/- cancers. 
 [H1] Diagnosis, screening and prevention  
[H2] Clinical diagnosis 
Diagnosis of retinoblastoma is usually clear from presenting signs and clinical examination.3 The most common 
sign is leukocoria (white pupil) (Figure 5). When parents report a strange reflection in the child’s eye, 
retinoblastoma should be at the top of the differential diagnosis. The second most common sign is strabismus 
(misaligned eyes) when central vision is lost. Advanced disease may present with iris colour change, enlarged 
cornea and eye due to increased pressure, or non-infective orbital inflammation. Very late, the eye may bulge 
from the orbit, a common presentation where awareness and resources are inadequate.  
Diagnosis of retinoblastoma does not rely on histopathologic examination since biopsy incurs risk of 
metastasis.72 Indirect ophthalmoscopy with the pupil pharmacologically dilated is usually sufficient for 
diagnosis by an eye specialist. Calcification, a characteristic of retinoblastoma, is detected by ocular 
ultrasonography (b-scan). MRI is used to assess invasion of the optic nerve73 and the presence of trilateral 
retinoblastoma (pinealoblastoma and primitive neuroectodermal intracranial tumours associated with RB1 
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mutations).73,74 CT scans are now avoided because radiation induces second primary cancers in people carrying 
RB1 mutations.75 
Detailed retinal examination under general anaesthesia is required to distinguish the differential diagnoses 
(Coats’ disease, persistent foetal vasculature, and vitreous haemorrhage) and classify the severity of intraocular 
disease. Accurate fundus drawing is essential to map tumour burden and location, and in some low-resource 
settings is the only available form of imaging. Where resources allow, the wide-angle, hand-held fundus camera 
is used to view and record the whole retina, while an expert depresses the sclera to bring the most anterior retina 
into view. At the same time that the focus is on viewing the anterior retina, care must be taken that there is not 
excessive pressure on the eye that could cause ischemia and would be indicated by optic nerve arterial 
pulsations. Very useful are high frequency (50 MHz) ultrasound biomicroscopy,76 and OCT63 to discover 
invisible tumours in infants with familial disease. Good imaging and documentation of the whole retina supports 
eye classification and cancer staging, documents treatment responses, supports consultation with colleagues, and 
helps parents understand treatment options.  
[H2] Classification and staging 
Classification is necessary to determine appropriate management and predict outcome. The Reese-Ellsworth 
classification77 for intraocular retinoblastoma was used to predict outcomes of external beam radiation. When 
new therapies became available, an international collaboration led by Murphree developed the International 
Classification of Intraocular Retinoblastoma (IIRC)78 which better predicted responses to intravenous 
chemotherapy than the Reese-Ellsworth classification (Figure 6).78 The IIRC classifies eyes in groups A to E, 
with E being the most severe. However, subsequent modification79 resulted in a significantly different versions 
of IIRC such that severely involved (dangerous) eyes are classified with less affected eyes.80 Subsequently, the 
Children’s Oncology Group (COG) inserted a further minor variation.81 The TNM cancer classification system 
for all cancers (defined by primary tumour (T), lymph node extension (N), and distant metastasis (M) is yet 
another slightly different system for retinoblastoma.82 The use of multiple classification schemes seeds 
confusion and undermines research in retinoblastoma. A priority to advance management strategies in 
retinoblastoma is to collect outcome evidence to develop one universally accepted classification based on 
evidence of the most important features at presentation that predict success for life and eye salvage, that will 
allow comparison between studies.  
A number of staging systems also exist for extraocular retinoblastoma. In a coordinated action with the group 
that developed the original IIRC78, retinoblastoma clinicians developed the International Retinoblastoma 
Staging System (IRSS), focused on overall staging (different again from the standard TNM).83 The American 
Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) staging system 
developed the TNM classification for retinoblastoma82, which is currently under revision for the 2016 edition. 
Owing to its general acceptance in the oncology field, this scheme has the potential to achieve a single, 
collaborative, consensus classification of eyes and cancer staging, critical to clinical research.  
10 
 
[H2] Pathology  
Histological examination of the retinoblastoma after enucleation of the affected eye (Figure 3) is the only way to 
evaluate high-risk features (tumour invasion into the optic nerve beyond the confines of the eye or to the cut end 
of nerve; more than 3 mm of invasion of the vascular layer (choroid) under the retina; invasion of sclera) and 
establish pathological staging.84-86 Emerging evidence indicates that high grade anaplasia (loss of differentiated 
characteristics) may be a risk factor for metastasis and death.87 High-risk features by the Murphree IIRC78 were 
observed in 15–33% of Group D and 50–61% of Group E eyes,85,88, but by the Shields IIRC (which classifies 
less affected D eyes as E), only 24–39%89 of Group E eyes showed high risk. Adjuvant systemic chemotherapy 
after high-risk features are observed in an enucleated eye may reduce risk of metastatic relapse.88-90 
The preparation and examination of the enucleated eye have been optimized to evaluate all risk features.84,91 
Pathology specimens are staged using the pathology TNM (pTNM) and the IRSS classification schemes.82,84 
However, still too frequently retrospective examination finds a previously unnoticed risk after metastatic disease 
is diagnosed. Staining of specific markers for photoreceptor cells (the cone-rod homeobox transcription factor; 
CRX)92 and for tumour cells (N-glycosylated ganglioside; NeuGc-GM3)93 may facilitate detection of tumour 
cells otherwise missed or interpreted as artefact.  
[H2] Genetic diagnosis 
Many patients with retinoblastoma are the first individuals to be diagnosed in a family; only 6% of patients 
indicated when tested for RB1 mutations that a family member was previously diagnosed with retinoblastoma.94 
However, a population-based study in England suggested that 35% of bilaterally affected patients had a family 
history.9 In three population-based studies9,11,95 representing 2,738 retinoblastoma patients on three continents, 
30–37% of cases were bilateral. When we add the 15–18% of unilateral cases who also carry an RB1 mutant 
allele, approximately 45% of people with retinoblastoma carry one RB1 mutation in their constitutional cells. Of 
the remaining patients with unilateral retinoblastoma, 98% have somatic biallelic RB1 loss and 2% have normal 
RB1 genes in the tumour, but somatic amplification of the MYCN oncogene instead.57  
Knowledge of the patient’s RB1 mutation profile enables precise screening of relatives and subsequent 
generations. Without genetic testing, all children at risk (already one eye affected and/or positive family history) 
should undergo multiple exams under anaesthesia in the first 3 years of life to enable detection of small, easily 
treatable tumours. When genetic testing reveals RB1 mutations in a family, children at risk can be tested for that 
mutation. Of unilateral patients, 85% will test negative with <1% residual risk for undetectable low level 
mosaicism, which reduces the intensity of surveillance for tumours in the normal eye and improves estimates of 
cancer risk of family members.8 In familial retinoblastoma, prenatal screening can be performed on DNA 
obtained from amniotic fluid. When such prenatal testing results in a positive finding, the retinoblastoma team 
works with specialists to safely induce labour near term, to facilitate detection and treatment of retinoblastoma 
tumours as early as possible.8 Pre-implantation genetic diagnosis for the known mutation of a parent offers the 
option for a family to have an unaffected child.96,97 
Cerebrospinal fluid and bone marrow can be molecularly screened to as part of a surveillance strategy, when 
clinically indicated, to detect metastasis. Harvested stem cells to detect minimal residual disease. Markers that 
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have been used are the RB1 tumour mutation (when mutation is not present or different in the germline 
alleles),98 the signature of post-RB1 genomic gains and losses99 and CRX expression.92 
Best outcomes in familial retinoblastoma management depend on the effectiveness of the healthcare team to 
identify and counsel affected families. Parents need appropriate genetic counselling and understanding of the 
risks and actions for each at-risk pregnancy. Alarmingly, a study of retinoblastoma in several developing 
countries observed that familial cases were diagnosed later than non-familial probands.100 The authors inferred 
that the parents did not understand the risks to themselves and/or to their children, or were afraid that there was 
no treatment available. Alternatively, socioeconomic or geographic barriers may have reduced desired 
healthcare access. Clearly, study of social determinants of health, such as health seeking behaviour, perceptions 
of medical care, and sociocultural issues related to cancer inheritance would inform counselling approaches that 
meet the needs of families.101 
[H2] Screening  
[H3] Screening through eye examination  
To detect retinoblastoma as early as possible, vision screening and eye examination have been developed. 
Childhood vision screening with effective training to detect signs of retinoblastoma will occasionally identify a 
child with retinoblastoma. Red-eye reflex examination is recommended and sometimes mandated for each 
doctor’s visit of babies and toddlers in many parts of the world, yet this does not often identify children with 
retinoblastoma. A negative childhood eye screening test does not mean this child will remain tumour-free since 
a tumour might appear later, or may have been in the periphery and not visible (false negative).  
An effective way to achieve early diagnosis is for all health professionals to be aware of retinoblastoma and the 
common words that parent use universally to describe the white pupil (Figure 5) that they have observed, and 
know that this might mean a life-threatening condition in the child that needs urgent attention. Too often health 
workers fail to take the parent’s complaint seriously, due to lack of awareness. Photoleukocoria (the appearance 
of leukocoria on flash photographs, Figure 5) can bring retinoblastoma to the attention of parents, but is 
hindered by red-eye reduction in the camera, which constricts pupils with a pre-photograph flash, limiting 
photoleukocoria detection.3 Red-eye and pet-eye correction tools to make portraits prettier removes 
photoleukocoria from photos, which might delay diagnosis. Awareness campaigns bring retinoblastoma to 
attention, but lose effectiveness with time. An innovative study called PhotoRed in India trained healthcare 
professionals to use flash photography to identify childhood eye diseases, including retinoblastoma.102 Other 
pioneering efforts target software to enable cameras to detect photoleukocoria.103 The global imaging industry 
could play a role in early diagnosis of retinoblastoma. 
[H3] Surveillance 
Individuals with germline RB1 mutation who have been treated with radiotherapy have high risk to develop 
specific second cancers (50% risk to develop cancer at 50 years if they received external beam radiotherapy 
(EBRT)), including leiomyosarcoma, osteosarcoma, melanoma, lung and bladder cancer.104 Surveillance 
screening for second cancers with and without radiation is a pressing need in the opinion of retinoblastoma 
survivors.105,106 The first study to evaluate annual whole body MRI surveillance for individuals with 
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predisposing RB1 mutation showed it was feasible to detect second cancers, however only with 67% sensitivity 
and one false negative test.107 Efforts to detect second cancers earlier are important to reduce mortality.  
In addition, lifestyle counselling educates survivors on ways to mitigate their second cancer risk by reporting 
unexplained lesions, and avoiding an unnecessary radiation and carcinogens (e.g. cigarettes and excessive 
alcohol). The extent to which these ideas will prevent second cancers is unknown. 
[H1] Management  
Management of retinoblastoma depends on extent of disease at diagnosis (classification of intraocular disease, 
stage of systemic disease), status of the opposite eye, overall health of the child, socioeconomic 
circumstances108, and access to expert care.3,21,109  
[H2] Intraocular retinoblastoma 
[H3] Primary treatment 
Choice of primary treatment is based on likelihood of cure (patient survival), eye salvage and ultimate vision, 
and the status of the other eye, weighed against short term and long term complications of treatment (Table 
3).109 In order of approximate frequency of global use, primary treatments for intraocular disease include 
enucleation, intravenous chemotherapy (IVC) with focal therapy (laser therapy, cryotherapy), intra-arterial 
chemotherapy (IAC) with focal therapy, and focal therapy alone when tumours are small at diagnosis. External 
beam radiotherapy (EBRT) is no longer recommended for first line therapy for primary intraocular 
retinoblastoma, since radiation, especially in the first year of life, imposes a high risk of secondary cancers when 
the patient carries an RB1 mutation.104,110 Although there is no role for EBRT in primary treatment of intraocular 
retinoblastoma, for salvage of the only remaining eye that has failed other therapies, EBRT may still have a role.  
Comprehensive analysis of the published literature on eye salvage by any strategy is confounded by the use of 
five different classification systems77-79,81,82 in different studies (Figure 6), preventing a clear-cut comparison of 
results between centres, especially for Group D and E eyes. There is a general consensus that eyes with clinical 
features such as neovascular glaucoma, pthisis bulbi (a shrunken, non-functional eye), and anterior disease are 
not appropriate for any conservative therapy and require enucleation to know if further therapy is needed for 
high risk pathlogical features.79,85,88,89 This may be particularly problematic when IAC is offered for eyes with 
advanced disease, since only the eye receives the chemotherapy.79,85,88,89 Clinical variables strongly associated 
with high risk features included older age, longer lag from diagnosis to enucleation, anterior tumour or blood, 
scleral invasion, invasion of the post-laminar optic nerve and orbital cellulitis.89,111,112 Attempted salvage by any 
method of an eye with features indicating high risk for extraocular extension imposes the danger of undiagnosed 
disease with risk for metastasis. By the Murphree IIRC78 high-risk features were present in 15–33% of Group D 
and 50–61% of Group E eyes85,88, and by the Shields IIRC79 24–39%89 of Group E eyes showed high-risk. 
Enucleation of the high-risk eye alerts those in the circle of care consideration of adjuvant chemotherapy to 
reduce risk for metastatic disease.88-90 If enucleation of Group78 E eyes is delayed longer than 3 months, for 
example by prior systemic chemotherapy, disease-specific survival is significantly lower (p<0.001).113 
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Choices for primary bilateral advanced retinoblastoma are outlined in Figure 7. However, where there is lack of 
expertise, equipment, resources, and difficulties with close monitoring, bilateral retinoblastoma may still be best 
treated with bilateral enucleation.3,21 Many bilaterally enucleated retinoblastoma survivors lead active, 
productive and satisfying lives because they were treated by timely surgery as infants. 
[H3] Second-line (salvage) therapy  
Second line salvage means initiating a new management plan, in a second attempt to save an eye that has failed 
the first attempt. A range of modalities is appropriate, but each subsequent plan has a lower success rate114 and 
long drawn out attempts to salvage an eye incur high risks for the child and family, including metastasis and 
death.108,115,116 
Second line treatment options include focal therapies, repeated systemic chemotherapy,117,118 IAC,114,119 
brachytherapy (internal radiotherapy),120,121, EBRT122-124 and whole-eye121 or proton beam125 radiation. Criteria 
for secondary enucleation are not well defined but are dominated by refractory subretinal and vitreous seeding, 
vitreous haemorrhage and secondary neovascular glaucoma,117,126 and socio-economic and psychological fatigue 
to save an eye with poor vision.108  
IVC and focal therapy could avoid EBRT and enucleation in 37–47% of Group D or Reese-Ellsworth Group V 
eyes in three studies with long-term follow-up.124,126,127 The three studies of IAC with the most patients128-130 
suggest that IAC achieved eye salvage in 57% of more advanced eyes, and a higher % of less advanced eyes 
using less focal therapy than is required to consolidate primary care following IVC. A combination of repeat 
IAC and intravitreal chemotherapy may play an important part in saving eyes that have failed IVC, radiation or 
IAC.119,130,131 However, in general, extensive treatments over a long time to save an eye may increase family 
stress, decrease family resources,108 and risk metastases and death.114,116,129 
Vitreous seeding is the major cause of failure to save or salvage an eye. Pharmacokinetic studies show poor 
vitreous levels of drugs administered by either IVC or IAC.132 The highest drug bioavailability in the vitreous is 
achieved by intravitreal chemotherapy using a safety-enhanced injection technique in carefully selected eligible 
eyes.133 Following control of the source of seeds, intravitreal chemotherapy achieved two-year 98.5% control of 
target seeds and 90.4% event-free ocular survival.133-135 The efficacy of intravitreal and IAC chemotherapy may 
ultimately eliminate the need for EBRT, even as second line therapy. 136A combination of repeat IAC and 
intravitreal chemotherapy may play an important part in saving eyes that have failed IVC, radiation or 
IAC119,130,131 However, in general, extensive treatments over a long time to save an eye may increase family 
stress, decrease family resources,108 and risk metastases and death.114,116,129 
A combination of treatments can target salvage therapies to the site of relapse. For relapse confined to the retina 
and/or vitreous, focal therapy and/or intravitreal chemotherapy are recommended, as long as whole-eye therapy 
is not required. Recurrent tumours that touch the optic nerve head and/or vision-critical regions such as the 
maculo-papillary bundle, or have a diffuse shallow retinal or subretinal tumour represent good indications for 
IAC, which might achieve better visual outcome than focal treatments.114,119  
14 
 
[H2] Ocular therapies 
[H3] Enucleation 
Enucleation is a first-line therapy for the majority of eyes with retinoblastoma globally; it is the fastest and least 
costly treatment137,138. Since the majority of children without a family history of retinoblastoma have Group78 D 
or E disease at diagnosis, and more than 50% have unilateral disease with the other eye unaffected, cure can be 
achieved with enucleation (Table 3). Most Group78 E eyes require enucleation because they carry risk of 
extraocular spreading by definition which can only be confirmed by the identification of high-risk pathological 
features in the enucleated eye. Good cosmetic outcome is achieved by replacement of the volume of the eye 
with an implant deep in the orbit, and provision of a prosthetic eye, worn in the conjunctival sac behind the 
eyelids (Figure 8). Many different reconstruction techniques are used worldwide.139 Comparative studies have 
shown best artificial eye motility with a simple, cheap, polymethyl methacrylate implant and muscles sutured to 
the conjunctiva to form the pockets to hold the artificial eye (myoconjunctival approach), which is affordable 
world-wide.140,141 Porous implants that become vascularized with muscles sutured to the implant are commonly 
used but are susceptible to infection and extrusion, and are more costly. Provision of a temporary prosthetic eye 
at the time of enucleation has a positive psychological impact on families,19 to help the family accept 
enucleation for their child. 
[H3] Intravenous chemotherapy and focal therapy  
Since 1996{Ferris, 1996 #7587} first-line therapy to control Groups78 B, C and D disease has been IVC with 
different combinations, doses, schedules, and durations of carboplatin, etoposide and vincristine (CEV) 
followed by focal therapy to consolidate chemotherapy responses (Figures 7, 9). {Chan, 1996 #10251;Gallie, 
1996 #10578;Shields, 2002 #9137;Manjandavida, 2014 #21453} One initiated RCT142 includes high–dose, 
short-duration cyclosporine simultaneous with the chemotherapy to modulate multidrug resistance.142,143 Eyes in 
Groups78 B and C do well with CEV and focal therapy. In three studies with long-term follow-up of IVC and 
focal therapy, 47% of Group78 D eyes124, 47% of Reese-Ellsworth Group V,126 and 47% of Group{Shields, 2006 
#21122} D eyes{Shields, 2006 #21122} avoided EBRT and enucleation (Figure 9).  
Fundamental principles for systemic cancer therapy also apply to retinoblastoma: optimized outcomes are 
anticipated with high dose intensity and combination of several agents with complementary mechanisms of 
action and optimal delivery to the eye. This is illustrated by the reduced effectiveness of single agent, low dose 
carboplatin for retinoblastoma.144 Acute toxicities of IVC for retinoblastoma are as for other paediatric cancers, 
including short-term transient pancytopenia (reduction in red blood cells, white blood cells and platelets), hair 
loss, vincristine-induced neurotoxicity, and infections. Long term toxicities include carboplatin-induced 
ototoxicity (high tone hearing loss) in some patients,145 second non-ocular cancer risk with alkylating agents95,146 
and secondary acute myeloid leukaemia following intense chemotherapy including topoisomerase inhibitors, 
doxorubricin and alkylating agents.147,148 
IVC alone rarely eradicates the retinoblastoma entirely, and focal therapy with repeated examinations under 
general anaesthesia is very important (Figure 9).126,149,150 Tumours in the macular region, threatening vision, are 
particularly at risk of recurrence without focal therapy,151 perhaps because of caution to not damage vision 
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results in under-treatment. Optical coherence tomography can be used to monitor macular tumours and scars for 
small recurrences, improving outcomes.152 
Location of tumour is the most important predictor of final visual acuity (near-normal visual acuity ≥0.5 in 22% 
of eyes with macular tumour, 67% of eyes with extrafoveal tumour).153 In children with two eyes affected, 
patching of the better eye to force use-dependent development of the eye with macular involvement (occlusion 
therapy) achieved near-normal vision in 53% and useful vision in 73% of patients.154 There is no documented 
local toxicity of IVC to the eye (Table 3).  
[H3] Intra-arterial chemotherapy  
IAC has been used for eye salvage therapy for decades in Japan129 and has been recently refined to achieve a 
more selective delivery to the eye.128,155 Interventional radiologists pass a micro-catheter through the femoral 
artery up to the orifice of the ophthalmic artery of the eye with retinoblastoma, and chemotherapy (single drug 
or combination; melphalan, topotecan, carboplatin) is infused in a pulsatile fashion over 30 minutes. Different 
interventional approaches are used for specific anatomic situations.156  
The three papers with mean follow-up 13 to 79 months and a total of 488 patients128-130 suggest that IAC 
achieved eye salvage for 65% of all eyes (Figure 10). Overall globe (eyeball) salvage was 74% when IAC was 
used as first-line treatment and 67% when used as second-line treatment.130 In the North American 
experience,130,157 globe salvage without needing EBRT (definition of “success”) was 96-100% for less advanced 
eyes (IIRC A-C or RE I-III)  and 94% for Group79 D eyes and 36% of selected Group E eyes79 with a median 
follow-up time <24 months; 80% of RE V that received OAC as primary treatment could be saved (n=36). The 
longest follow-up study (median 74 months; range 0–252 months) for IAC salvaged the eye in 88% of Group B, 
65% of Group C, and 45% of Group D eyes with vision ≥0.5 (Vision decimal system, 1 = normal, 0.1=legal 
blindness) in 50% of the eyes that had no foveal involvement.129 This evidence suggests that IAC is a reasonable 
approach to primary therapy for eye salvage, with good evidence for a role in secondary eye salvage.114,119  
From the IAC publications, the total number of patients with metastases is unclear, but at least 14 are 
reported.116,128,129,158 Since many other treatments were given simultaneously with IAC, the 8 deaths from 
metastases of 343 patients with long follow-up129 are not clearly assigned to IAC alone. From the IAC 
publications with high patient number and longer follow-up, metastatic relapse occurred in <2% of the children 
receiving IAC, but the relapsed patients often had received extensive, multimodal therapies116,128,129,158. The long 
term Japanese experience129 and the more recent New York experience128 have not reported an increase in 
metastases or metastatic deaths to date. 
Ocular complications of IAC included vitreous haemorrhage (2%), branch retinal artery obstruction (1%), 
ophthalmic artery spasm with reperfusion (2%), ophthalmic artery obstruction (2%), partial choroidal ischaemia 
(2%) and optic neuropathy (< 1%).130 At the time of IAC, minor transient complications included transient 
eyelid oedema (5%), blepharoptosis (droopy eyelid 5%), and forehead increased blood flow, 2%).130 
Electroretinogram showed minor evidence of retinal toxicity which lasted up to 12 months, which was not 
considered clinically relevant.159  
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[H3] Focal therapy 
Focal therapy (laser therapy, cryotherapy, local chemotherapy) is the local application of therapy to the eye, 
under direct visualization through the pharmacologically dilated pupil. Focal therapy is the primary treatment 
for Group78 A eyes and is used to consolidate responses of Group78 B, C, D eyes after IVC or IAC with the aim 
to physically destroy residual or recurrent small-volume, active retinoblastoma. In general, focal therapy is 
repeated monthly until the tumour is completely atrophic or calcified (Figures 8, 9).  
Two types of laser treatments are applied monthly until the tumour is flat, atrophic or calcified. Transpupillary 
thermotherapy involves a 810 nm diode laser through the dilated pupil to heat tumour, rather than precisely 
coagulate the tumour for 3–5 minutes per spot. Photocoagulation lasers with 532 nm, 810 nm or continuous 
wave 1064 nm laser beams are directly applied by multiple short (0.7 s) burns to small volume active or 
suspicious tumour, gradually increasing power from sub-coagulation power intensity until the tumour is 
coagulated opaque white. Cryotherapy, on the other hand, involves freezing the tumour through the sclera with a 
nitrous oxide probe; the tumour is directly visualized and duration of freeze judged to completely eliminate the 
tumour. Since tumour cells die when thawing, one minute is allowed for each thaw between freezing cycles. 
Cryotherapy effectively destroys small primary tumour(s) or recurrences in the periphery of the retina. Plaque 
radiotherapy involves positioning a radioactive probe on the eye to deliver trans-scleral radiotherapy with an 
apex dose of 35–40 Gy over 4–7 days. Plaque focal radiation has not been associated with new primary tumours 
and is effective to treat a single primary or recurrent tumour in a location that will not compromise vision. 
Finally, paraocular chemotherapy has been useful for small volume recurrences and vitreous seeds.118,160-162 
[H3] Intravitreal Chemotherapy 
Primary treatments mainly fail due to the presence of vitreous seeds.118 Intravitreal chemotherapy is adjunctive 
to other treatments, and is only initiated after the source of the seeds is controlled. The use of intravitreal 
chemotherapy to control vitreous seeds — most difficult to control form of retinoblastoma — has been 
promising, especially in combination with a safety-enhanced injection technique and well defined eligibility 
criteria.133,135,136,163,164 Under anaesthesia, the intraocular pressure is lowered by removing a small volume of 
fluid from the anterior chamber or by digital massage. Melphalan (or combined with topotecan) is injected into 
the vitreous behind the lens, through the conjunctival, sclera, and pars plana with a small-gauge needle. On 
needle withdrawal, the injection site is sealed and sterilized with cryotherapy and the eye is shaken gently to 
distribute the drug throughout the vitreous. Three clinically defined classes of vitreous seeds have significantly 
different median times to regression, mean number of injections and cumulative and mean melphalan dose.135 
Ultrasound biomicroscopy may be used to evaluate the otherwise hidden ciliary region behind the iris76 to 
confirm that the injection site is tumour-free prior to intravitreal chemotherapy treatment. The toxicity of 
intravitreal chemotherapy is limited to technique-dependent localized peripheral retinal toxicity.136 
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[H2] Extraocular retinoblastoma 
[H3] Extraocular at presentation 
Retinoblastoma may present with evident extraocular disease, especially in low-income countries. Orbital 
extension of an intraocular retinoblastoma may be detected clinically in children with proptosis or a fungating 
mass or occasionally by imaging studies. Treatment includes neo-adjuvant chemotherapy, including carboplatin, 
etoposide and vincristine, as for intra-ocular retinoblastoma; other agents that are useful include cisplatin, 
cyclophosphamide and anthracyclines.21 This is followed by enucleation and limited excision of affected tissues 
without mutilation, orbital radiation and adjuvant chemotherapy. Intrathecal chemotherapy (injection into the 
cerebrospinal fluid space) may also be used and high dose chemotherapy with stem cell rescue may be added in 
metastatic disease. Children with orbital disease or metastatic spread without central nervous system invasion 
may be cured with intensive therapy. Long term outcomes for retinoblastoma patients presenting with 
extraocular disease are complicated by late-developing effects, but overall they are moderate.165  
[H2] Palliation  
Palliation includes pain management, symptom relief, nutritional support, and psychosocial support for the child 
and families.21 Untreated retinoblastoma is highly sensitive to most chemotherapy agents. Children presenting 
with orbital retinoblastoma are usually in severe pain and discomfort that may be alleviated with judicious use 
of anticancer therapy, including conventional chemotherapy, even when no curative intent is pursued. These 
children often present with severe emaciation (severe weight loss) needing prompt medical treatment. 
Radiotherapy may also be helpful, especially for a central nervous system relapse or for the treatment of 
massive orbital extension, but it is often unavailable in low-income countries.166 
[H1] Quality of life  
Quality of life (QoL) describes the level of physical, emotional and psychological wellbeing experienced by an 
individual. Cancer, its treatment and effects on the developing body, brain and mind can significantly decrease 
QoL, which has implications for treatment decisions and supportive and long-term follow-up care. 
[H2] Measured life-long impact  
In one study, children with retinoblastoma followed from diagnosis to age 5 years showed decline in 
developmental functioning over time.167 However, survivors diagnosed under 1 year of age performed 
significantly better in short-term and long-term verbal memory, verbal learning and verbal reasoning abilities 
compared with those diagnosed at over 1 year of age.167,168 Surprisingly, verbal IQ was significantly above both 
age-matched sighted and non-retinoblastoma blind persons.169 This unexpected higher performance might relate 
to the heritable RB1 mutant allele in the younger children, since the opposite outcome is expected in this group.  
Adults who lost one eye to retinoblastoma in early–life have altered development of visual, auditory and 
multisensory brain morphology, suggesting that the remaining eye acquired increased contralateral visual and 
other cortical connections, also measured as enhanced functioning of the remaining eye, if the other eye is 
removed at a young age.170-172 However, clinical and animal studies suggest that repeated anaesthesia of young 
children, such as is necessary for eye salvage and to discover and treat small tumours, may impair 
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neurocognitive development.138,173,174 Clearly the long-term development of retinoblastoma survivors is an 
important area for future study, to both guide future care of newly diagnosed children and survivors, and learn 
about human development. 
 [H2] Direct insight from survivors 
Social media have brought parents of patients with retinoblastoma and survivors into peer-support communities 
that share experiences and insights with each other. It is not yet clear how to reference and include the unique 
and rich data of social media in formal research.  
Children’s perception of pain and medical interventions changes over time.175-177 Since children with 
retinoblastoma have to undergo many repeated procedures, normal anticipation anxiety around procedures might 
be magnified, resulting in intolerance of even minimally invasive experiences and mild pain. The child’s initial 
strong emotions may be suppressed as the child gives up, and re-emerge as depression, post-traumatic stress or 
developmental trauma disorder.115,178-180 Child Life interventions at any age and with any treatment help children 
cope and even thrive during treatment, reduce treatment costs, ease family stress and improve long-term mental 
health (Figure 11).5,75,181-184  
Retinoblastoma treatment is often the childrens’ only life experience and forms the centerpiece of their earliest 
memories. Adult survivors may not remember being anaesthetized, however, many describe acute fear of their 
mouth and nose being covered. Extended isolation during therapy may impact social functioning. Although 
most adult survivors perform well socially, many report low confidence and intense anxiety, especially in large 
groups and crowded environments. Most survivors are high cognitive performers.168 However, reduced vision 
causes some children to become frustrated by their inability to keep up with peers, damaging self-esteem and 
confidence.165,185,186 
[H2] Late effects of radiotherapy 
Although radiotherapy is nowadays rarely used for primary treatment of retinoblastoma, thousands of adult 
survivors live with its long-term effects. Many feel neglected and demoralized by lack of follow-up and 
prospective management. Facial deformity induced by radiation blocking tissue growth causes low self-
confidence and social anxiety. Reconstructive surgery is a painful process that may impact remaining vision, but 
its cosmetic effects can dramatically improve QoL. Dry eye is very painful, and corneal vascularization reduces 
already limited vision. Use of ocular lubricants may prevent complications, if started early before pain and 
vision loss occur.  
[H2] Second cancer risk 
Individuals at risk of second primary cancers as a consequence of RB1 gene mutation require life-long follow-
up.95,104,187 Lack of agreed-upon protocols causes confusion, frustration and fear as adults struggle to access 
informed care, compounded by primary doctors who are not aware of late effects and life-long implications of 
RB1 mutations. Looking forwad, full information about the patient’s cancer history, genetic status, life-long 
risks and action plan when concerns arise will empower survivors to be advocates for their own and their 
children’s health .188-191  
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[H2] Family planning  
Many adult survivors have little knowledge of retinoblastoma genetics, genetic counselling or testing, their own 
status, or options for their baby. Genetic testing provides knowledge of inheritance of the parental RB1 mutant 
alleles, empowering several options.8 Pre-implantation genetic diagnosis is expensive but available for parents 
with retinoblastoma in some countries96,97. Choices for an affected foetus are complex and dependent on social 
contexts. Parents seek an agreed-upon screening protocol for at-risk babies, and the discussion and planning 
may cause, or remove anxiety among survivor-parents. Anger and guilt about somehow being responsible for 
the child’s cancer is amplified when diagnosis is delayed. Screening protocols for at-risk children will reduce 
survivor-parent anxiety and enhance early diagnosis to achieve minimally invasive therapy. 
 [H1] Outlook  
Retinoblastoma is curable if diagnosed early. We propose that within 10 years retinoblastoma can be a ZERO-
death cancer. Our anti-retinoblastoma arsenal will consist not only of curative treatments, but also measures to 
prevent development of disease in predisposed individuals. To achieve this vision, critical efforts are needed to 
build upon the current state-of-the-art for retinoblastoma as presented in this Primer. Here, we outline the key 
action items, respond to the immediate obvious targets for improvements, and set the stage for innovative 
discoveries in retinoblastoma (Box 1). We are confident that the 8,000 children that will be diagnosed each year 
will have optimized timely diagnosis, stage-appropriate care, and survive and have productive, happy lives. We 
are also inspired by the principles that define a “High Reliability Organization”192 such as decision support tools 
based on evidence; deep analysis of unexpected events (such as metastasis unexpected for the stage at 
presentation, technical errors, failure to achieve parental compliance) and action to prevent such events; and full, 
honest and open communication.  
We propose to determine the most likely cause of every death from retinoblastoma. Similar in concept to the 
groundbreaking Million Death Study,193 each death will be an opportunity to avoid more deaths. The identified 
key risk factors will lead to systematic guidelines to avert preventable deaths. These guidelines will fall into 
categories such as public awareness (public and health system understanding of the urgency of leukocoria, use 
of social media), health services194 (infant screening, financial support for every child, regional retinoblastoma 
expertise, etc.), clinical research (co-operative groups for clinical trials, outcomes analysis from learning health 
records, etc.) and basic research (define in retinoblastoma tumour cells targets for new therapy, define molecular 
targetable pathways for treatment and prevention of RB1-/- cancers, starting with heritable retinoblastoma).  
[H2] Patient-centered, global research  
Retinoblastoma will benefit from clinical science at the level that has achieved dramatic change for paediatric 
cancer. In retinoblastoma, we have lagged behind in systematic accumulation of evidence on which to base 
therapy. Today we are faced with sweeping change in treatment of retinoblastoma using IAC and salvage of 
unresponsive vitreous seeds by intravitreal chemotherapy. However, we do not have full data on which to judge 
patient eligibility, long-term effectiveness or outcomes. In-depth systematic reviews and meta-analyses of 
therapies and outcomes for retinoblastoma can capture retrospective evidence on which to base present 
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recommendations for therapy. Global collaboration will empower RCTs of many aspects of care for children, 
families and survivors of retinoblastoma. 
We have opportunities now to learn from initiatives and innovations everywhere, and to listen to the patient’s 
voice to become an inclusive, participatory global network. Patients and families, empowered by social media, 
will be heard in the research approaches, making these approaches relevant, ethical, and appropriate. 
Stakeholders from low-and-middle income countries will be active innovators, assuring that protocols are 
feasible and acceptable. Equality for retinoblastoma will come by education (internet access), with shared 
collaborative care coordinated online. Retinoblastoma expertise will be developed locally (proportional to the 
local burden of retinoblastoma) but derived globally, with best practices drawing on rigorous molecular and 
clinical research. Broad inclusion in high quality studies of all aspects of care, including traditional, 
complementary and alternative medicine, will enhance outcomes.195 Retinoblastoma RCTs will be collaborative, 
high-enrolment studies. Effective innovations will include all outcomes (survival, eye salvage, short- and long-
term toxicities, social impact, etc.) and sustainability (cost, uptake by health ministries, social acceptability of 
therapy, etc.). The global burden of retinoblastoma shows the inherent inequity in how patients are diagnosed 
and cared for around the world.5 Documentation of human and material resources required for optimal care, 
drawn from established clinical care guidelines, represents a first step towards health equity. National strategies 
in areas currently under represented in the retinoblastoma literature are poised to fill the knowledge gap.  
We need a universally endorsed single classification in order to avoid confusion regarding eligibility and 
salvage rates for new treatments. Progress in therapy is critically dependent on achieving consensus on a 
standard classification of intraocular disease. The ongoing AJCC/UICC international survey of features of eyes 
at diagnosis, treatments given and outcomes will be used to derive one evidence-based classification to replace 
the current clinical staging schemes that confuse analysis, eligibility and outcomes.78-80,82 
We are poised to collect uniform data on all children with retinoblastoma. The 1RBW.org map documents 
“staff, stuff systems and spaces”196 and provides an alternative system of global collaboration, perhaps unique to 
small neglected diseases, but possibly a fore-runner for future learning health systems. The eCancerCareRB 
(eCCRB) point-of-care database summarizes the health record from diagnosis (including features of eyes and 
patient, treatments, complications, and outcomes) and is available to all retinoblastoma centres.197,198 eCCRB also 
supports the caregivers and families by graphically displaying this information ensuring high motivation to 
collect good data quality by clinicians who directly benefit from efficient and accurate patient care (Figures 5, 8, 
9). The next phase of this online project (aiming at 2020) will combine the 1RBW map (http://www.1rbw.org) 
with eCCRB de-identified patient data to develop a ‘learning health system” which will provide real-time 
analysis of outcomes and will guide clinicians to apply evidenced-based care.199  
 [H2] Targeted therapies  
Our knowledge of the cell of origin of retinoblastoma and its unique sensitivity to RB1 inactivation is steadily 
increasing, and may reveal strategies to prevent tumourigenesis. Moreover, ongoing work to define the 
molecular signature of retinoblastoma will continue to yield novel therapeutic targets. Advances in therapeutic 
development and prevention depend on these molecular studies, but we do not yet have preclinical models that 
accurately reflect retinoblastoma pathogenesis and treatment.  
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One of the earliest targeted therapies envisioned for use in retinoblastoma, based on preclinical information 
generated in transgenic mice, was Nutlin-3.200 Nutlin-3 blocks the interaction of MDM2 and MDM4 with p53, 
resulting in stabilization of p53 and stimulation of apoptotic cell death. Nutlin-3 showed promising activity in 
combination with topotecan for retinoblastoma control in preclinical models. Although the SYK antagonist 
R406 was also considered a promising candidate based on preclinical studies,53 its ocular pharmacokinetic 
profile following peri-ocular administration rendered it unfavourable for clinical use.201 Preclinical studies 
further suggest that retinoblastoma initiation and tumor growth might be suppressed by inhibitors of MYCN, 
SKP2, E2F, or CDKs (Figure 12).  
Preclinical studies have also sought to identify and evaluate pharmacokinetics of new agents alone or in 
combination202 before clinical use. A few translational studies have resulted in changes in retinoblastoma 
clinical practice.203 Innovative delivery systems to target small-volume subretinal tumours and vitreous seeding 
include episcleral implants204 and nanoparticles205. Approaches adjusting chemotherapy schedules and dose 
intensity (metronomic therapy)206 may particularly play an important role in palliative care for retinoblastoma. 
New biomarkers for molecular dissemination of retinoblastoma outside the eye may lead to earlier diagnosis of 
metastasis and targeted treatments.92,93  
[H2] Quality of life  
Without thinking about the lifelong outlook for patients, however, all of the above endeavours become moot. 
Quality of life begins in infancy, assisted by Child Life181 and respect for the child’s need to play. Patient-
oriented research will develop and validate life-long survivor follow-up care protocols, including centralized 
specialist eye care, genetic testing, second cancer screening, ongoing psychological support and fertility care. 
The education of primary physicians and development of survivor clinics will reduce morbidity and facilitate 
research to inform patient management with a major outcome being good quality of life during treatment and 
throughout life. 
Display Item Legends  
Box 1: Outstanding research questions  
Patient-centered, global research focus 
• Collect outcome evidence to develop one universally accepted classification based on clinical features of the eye at presentation that predict success for life and eye salvage, that will allow comparison between studies.  
• Address the reluctance of health care workers to explain the true risks (such as in Jordan where doctors do not want to destroy families), and the choice of families who know and understand the risks but choose not to follow through because of stigma. 
• Define treatment success: cure (life), salvage of vision (one eye), salvage of eye (vision and cosmetic), fewest examinations under anaesthesia (cumulative toxicity of anaesthesia). 
• Meta-analysis of all children treated primarily with intra-arterial chemotherapy to quickly establish that this treatment is both safe and effective. 
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• Develop a “retinoblastoma index” to predict outcome and include levels of awareness, access to centres with the necessary resources and expertise, and application of evidence-based care.  
• Collect evidence about the quality of life following retinoblastoma, and develop action plans to address the issues that most affect survivors.  
• Determine what failures led to death of children from retinoblastoma, and focus global effects on these targets to make retinoblastoma a ZERO death cancer.  
• Implement a global retinoblastoma health record, such as eCCRB, to underpin a Learning Health System bringing real-time evidence to treatment choices. 
Pathogenesis 
• What underlies the genomic progression post RB1 loss? 
• What molecular changes promote (early) metastasis?  
• Are there other RB1+/+ genetic subtypes beyond MYCN-amplified retinoblastoma? 
• What dictates the tissue specificity of RB1 loss leading to cancer? 
• What are the molecular features of second cancers in RB1 mutation carriers?  
• Develop drugs with low systemic toxicity and high effectiveness against retinoblastoma. 
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Figure 1| Progression of retinoblastoma. a) Anatomical features of a healthy eye. Genomic damage (orange 
lightning bolt) leads to mutation of RB1 resulting in biallelic functional loss of RB1 in a developing retinal cell 
(possibly a cone photoreceptor precursor cell that is dependent on pRB to stop proliferation). b) Genomic 
instability leads to a benign retinoma; only 5% of patients show retinoma without retinoblastoma. Inset shows a 
small retinoma/tumour not visible except by optical coherence tomography. c) Intraretinal retinoblastoma arises 
as additional genomic changes promote uncontrolled cell proliferation; the tumour grows and seeds become 
independent, floating under the retina and into vitreous. d) Retinoblastoma can invade adjacent tissues: into the 
optic nerve, uvea, or sclera to constitute high-risk pathologic features. e) Eventually, retinoblastoma can extend 
extraocularly into orbit and metastasize especially to the bone marrow, or into the brain (direct or via the 
cerebrospinal fluid).  
Figure 2 | Global retinoblastoma treatment centres and patient distribution relative to resources. One 
Retinoblastoma World (www.1rbw.org) shows Retinoblastoma Centres of Excellence, providing a resource for 
affected families to access expert care. The majority of patients reside in low and middle income countries, 
while the majority of Retinoblastoma Centres are in high income countries. Images from www.1rbw.org.  
Figure 3 | Genetic origins of retinoblastoma. Three genetic subtypes of retinoblastoma are known. Heritable 
retinoblastoma patients have a constitutive inactivating mutation (M1) in the RB1tumor suppressor gene in all 
cells of their body. A second, somatic mutation (M2) in a susceptible retinal cell can lead to benign retinoma. 
Further genetic and/or epigenetic events (M3…Mn) are required to transform to retinoblastoma. Non-heritable, 
RB1-/- retinoblastomas progress similarly, except both M1 and M2 occur in one susceptible retinal cell. 
RB1+/+MYCN-amplified (RB1+/+MYCNA) retinoblastoma is a rare, non-heritable retinoblastoma subtype driven 
by amplification of MYCN with normal RB1; other changes in these tumours remain uncharacterized. Retinoma 
histology shows distinct photoreceptor-like fleurettes, whereas RB1-/- retinoblastoma can show Flexner-
Wintersteiner (insert) and Homer Wright rosettes (not shown). RB1+/+MYCNA retinoblastoma have a distinct 
morphology with rounded nuclei and prominent nucleoli related to the high MYCN protein.  
Figure 4 | Retinoblastomas originate in the retina. a, The retina has a complex structure and contains multiple 
cell types. Haematoxylin and eosin staining of post-fertilization week 19 retina shows three post-mitotic nuclear 
layers in the central retina near the fovea (left) and two nuclear layers in the less mature periphery of the same 
histologic section (right). Cell types in each layer are indicated. b, Cone precursors normally have high 
expression of the RB protein (pRB). Immunofluorescence staining of post-fertilization week 19 retina shows 
especially strong pRB signal (pink) in maturing cone precursors in the central retina (left, counterstained for 
cone arrestin, green) and in retinal progenitor cells in the peripheral retina of the same histologic section (right). 
pRB staining is less intense in DAPI-stained nuclei (blue) in other retinal cell types. c, Wide-angle retinal image 
(left image) shows no tumor. In the plane of the green line, optical coherence tomography (OCT; right image) 
shows a tiny intra-retinal tumor in a 2.5 month old infant, which seems to extend from the inner nuclear layer to 
the outer nuclear layer. The tumour has an uncertain epicentre making it difficult to infer the retinal layer from 
which the tumor arose. The layer-of-origin may be defined in the future with more images of higher resolution 
OCT of retina in very young children carrying an inherited germline RB1 mutation. Abbreviations: ONL, outer 
nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; NBL, neuroblastic layer; RPE, retinal pigment 
epithelium.  
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Figure 5 | Online diagnosis of retinoblastoma. a, Detection of photoleukocoria (white pupil) on this digital 
image led the parents to the diagnosis of retinoblastoma. The left eye was determined by examination under 
anaesthetic to have IIRC78 Group D retinoblastoma and was enucleated two days later; CT scan was scheduled 
to check for trilateral tumour. (Today, MRI would be recommended to reduce radiation exposure.) The 
pathologic examination of the eye showed no high-risk features. The other eye was normal at diagnosis but on 
the next examination a small tumour was detected and treated with only laser. b, One month after surgery, the 
child presented with high intracranial pressure. A large intracranial midline tumour (trilateral disease) was 
diagnosed on CT scan, which was treated with chemotherapy, high-dose chemotherapy with hematopoietic 
rescue by stem cell transplant, and intrathecal chemotherapy injections (directly into the cerebro-spinal fluid) 
through an implanted intraventricular catheter. c, Follow-up MRI at age 8 years shows no residual disease and 
d, the child is well with one good-looking artificial eye and one eye with normal vision; he wears poly-
carbonate lenses to protect his only eye. e, The eCCRB timeline of treatments; not all intrathecal chemotherapy 
injections (*) are shown.  
Figure 6 | Different classification schemes for intraocular retinoblastoma confound comparison of 
outcomes. The features listed determine the overall classification, ranging from small tumours not threatening 
vision (“Group A”) to tumours clinically noted to have features suggesting potential spread outside the eye 
(“Group E”). Most importantly, size of tumour alone does not make an eye dangerous by Murphree,78 
Children’s Oncology Group (COG),81 or TNM classification;82 but any eye with tumour >50% of eye volume is 
E (advanced-stage disease) by Shields classification.79 The consequence is widespread confusion in the 
literature undermining clinical research, since studies using the different classifications cannot be compared. 
The red boxes indicate the critical differences between the different classifications.  
Figure 7 | Primary treatment choices based on the Murphree IIRC. Treatment depends on the combined 
severity of each of the affected eyes (Eye 1 | Eye 2); the preferred option for each eye is depicted in the blue 
boxes. IIRC Group78 A eyes can be treated with only laser or cryotherapy (focal therapy consolidation). Group78 
B and C eyes require several cycles of systemic intravenous chemotherapy (IVC) or intra-arterial chemotherapy 
(IAC) followed by focal therapy and intravitreal chemotherapy with melphalan and/or topotecan for residual or 
recurrent vitreous seeds. Isolated single tumours in Group78 B or C eyes may occasionally be appropriate for 
primary radioactive plaque therapy. Group78 D eyes require either IVC (with focal therapy consolidation) or 
IAC (with focal therapy consolidation). All eyes with features suggesting imminent extraocular extension 
(Group78 E) should be removed so that accurate pathological examination can be performed to determine risk of 
metastasis requiring adjuvant chemotherapy. IIRC, International Intraocular Retinoblastoma Classification.78 
Figure 8 | Triplets with retinoblastoma. These triplets developed retinoblastomas in all six eyes illustrating 
the full expressivity and penetrance of RB1-/- germline mutations that completely abolish pRB expression. The 
pedigree indicates that the three children all have the same RB1 mutation, which is not detected in their parents 
or older brother. The eCCRB timelines reveal that all eyes had individualized therapy, with choices considering 
the overall impact on each child. Each child lost one eye, has a good-looking artificial eye and an eye with 
normal vision, and has disease control in less than one year. The number of eye exams under anaesthesia (EUA) 
was least for the child who had primary enucleation. OD, right eye; OS, left eye. Eye involvement at diagnosis 
is indicated in by the International Intraocular Retinoblastoma Classification;78 the eye labelled “Group 0” had 
no tumour at initial diagnosis but developed a tumour 6 weeks later.  
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Figure 9 | Retinoblastoma treated with IVC. a, Detection of photoleukocoria in both eyes at age 8 months. b, 
Retinal photography at diagnosis showed total retinal detachment with underlying large tumours in the right (left 
image) and left eyes (right image). c, Both eyes have calcified tumor remnants and attached retinas 20 years 
after diagnosis, with 0.25 vision, right eye and 0.1 vision, left eye (Vision decimal system, 1 = normal, 0.1=legal 
blindness). d, eCCRB time line of shows treatment with IVC and focal therapy, then only follow-up visits. 
Figure 10 | Retinoblastoma treated with IAC: a, Before IAC for a massive exophytic (outward growing 
tumour) retinoblastoma with total retinal detachment; and b, after IAC, showing complete response and eye 
salvage, leaving a 6 mm calcified scar. c, Before IAC for an endophytic (inward growing tumour) 
retinoblastoma tumour with extensive vitreous seeding; and d, after IAC showing complete control with 
clinically intact fovea and visual acuity 20/25. e, Before  IAC for an eye with macular retinoblastoma 
demonstrating excellent tumor regression away from the macula; and f, after IAC leaving intact fovea and hope 
for vision. 
Figure 11 | Child Life promotes effective coping through play, preparation, education, positive-touch and 
self-expression activities, based on natural child development. Child Life181 helps children and their families 
cope with challenging healthcare issues, hospitalization and therapeutic interventions. This child plays doctor 
and nurse, wearing gloves and stethoscopes to examine Puppet Kevin who had one eye removed for 
retinoblastoma. They also learn how to put in his artificial eye, to better understand their own artificial eye. Play 
(medical play and just general play) promotes a sense of control for children within their medical experience.   
Figure 12 | Proposed roles for cone precursor circuitry in retinoblastoma tumourigenesis and targeted 
therapy  
Signalling circuitry specific to maturing L/M-cone precursors is uniquely conducive to oncogenic 
transformation in response to pRB loss.49,61,62 Specifically, these cone precursors express the transcription 
factors RXRγ and thyroid hormone receptor (TR) β2, and high levels of MYCN, MDM2, and pRB, and down 
regulate p27 via a SKP2-related mechanism. pRB depletion in maturing cone precursors blocks cone 
photoreceptor differentiation and enables proliferation and survival dependent upon MYCN, SKP2, and MDM2. 
Mouse models suggest that E2Fs and CDKs contribute to the proliferative response to pRB loss59; these 
genes/proteins are also needed for proliferation and survival of human retinoblastoma cells.61,207 Identifying the 
molecular mechanism mediating the cone precursor proliferative response to pRB loss provides opportunities to 
prevent tumor initiation, at least in preclinical models. Potential drugs are inhibitors of MYCN expression 
(JQ1),208 inhibitors of MDM2-mediated p53 degradation (Nutlin 3a),200 inhibitors of SKP2-mediated p27 
degradation (C25),209 and inhibitors of E2F and CDK activities (HLM006474 and R547, respectively)59. In 
addition, SYK was highly expressed in retinoblastoma but not normal retina.53 Additional targeted agents may 
be effective against growing tumours, such as improved versions of the SYK inhibitor R406.53,201  
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Tables 
 
Table 1| Estimated global distribution of retinoblastoma. 
Category 
Population, 
total 
Birth rate, 
crude (per 
1,000 
people) 
Mortality 
rate, infant 
(per 1,000 
live births) 
Forecast 
live birth 
total 
Retinoblastoma 
incidence (high) 
1:16,000 
Retinoblastoma 
incidence (low) 
1:18000 
% of world 
retinoblastoma 
World 7 x 109 19.4 34.6 131 106 8,200 7,300 100% 
        
High income 1,299,489,520 11.6 5.5 14,941,320 934 830 11.4% 
High income: 
non-OECD 249,927,994 13.8 10.3 3,418,872 214 190 not applicable  
High income: 
OECD 1,049,561,526 11.0 4.4 11,518,845 720 640 not applicable 
Low & middle 
income  5,743,616,071 21.1 38.1 116,699,203 7,294 6,483 88.7% 
Middle income  4,913,580,797 19.2 33.7 91,300,546 5,706 5,072 69.4% 
Upper middle 
income  2,390,210,774 14.8 16.3 34,737,317 2,171 1,930 26.4% 
Lower middle 
income  2,523,370,023 23.4 45.3 56,490,388 3,531 3,138 42.9% 
Low income 830,035,274 32.3 54.5 25,373,890 1,586 1,410 19.3% 
Forecast births were calculated using most recent data (2012) on each World Bank Category for 
population, birth rate and mortality rate (World Bank (http://data.worldbank.org) accessed on 5 February 
2015. Low (1:18,000 live births) and high estimates (1:16,000 live births) for retinoblastoma were 
calculated, following the example of Kivela.5 Since retinoblastoma arises before and near birth, the usual 
cancer incidence rate calculations (number of cases diagnosed in a given population, sometimes adjusted 
for the under-514 or under-1411 populations in children’s cancers) do not provide accurate data for 
retinoblastoma. OECD, Organisation for Economic Co-operation and Development 
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Table 2 | Availability of treatment and imaging at retinoblastoma centres worldwide. 
Countries 
Total 
number 
of centres  
Enucleation 
(%) 
Laser 
therapy 
(%) 
Cryotherapy 
(%) 
IVC (%) 
Retinal 
imaging 
(%) 
High income  47 100% 91% 89% 85% 89% 
Middle income  75 100% 91% 91% 69% 63% 
Low income 10 100% 50% 20% 5 (50%) 30% 
Total  132 100% 88% 85% 97 (73%) 70% 
Retinoblastoma centres worldwide were surveyed and featured on the One Retinoblastoma World Map 
(1rbw.org, accessed on 25 March 2015). Information is available for 54 countries (22 high-income 
countries, 28 middle-income countries and 4 low-income countries, following World Bank 
Classification). The percentages depict the percentage of centres offering the specific treatment or 
diagnostic tools. IVC, intravenous chemotherapy. 
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Table 3 | Qualitative comparison of enucleation, IVC and IAC for unilateral retinoblastoma (Murphree IIRC Groups B, C, D).   Enucleation  IVC and focal therapy  IAC and focal therapy Treatment 
 
Major muscles removed, optic nerve cut, eye removed; orbital volume reconstituted with implant; muscles sutured to gain motility of the artificial eye, held in place by the eyelids. 
 Chemotherapy (carboplatin, vincristine, and etoposide) is given intravenously, best through an implanted "port", every 3-4 weeks; tumour response consolidated by focal therapy (laser and cryotherapy) every 1–4 months for 3 years. 
 Chemotherapy (melphalan, and/or carboplatin, and/or topotecan) infused via micro-catheter through femoral artery,   near, or into the ophthalmic artery with radiographic confirmation; tumour response consolidated by focal therapy (laser and cryotherapy), every 1–4 months for 3 years. Success rate to save eye (%) 0%  47% Group78 D; >90% Group B & C  45129 to 95130% Group78 D*; >90% Group B & C Acute toxicity Loss of eye; parental distress waiting for artificial eye fitting; transient bruising, swelling and headache 
 Hair loss; low white cell count; fevers require IV antibiotics and hospital admission; protective isolation at a time of social development; parental distress over prolonged treatment 
 Groin haematoma; transient low white cell count; potential carotid vascular spasm and stroke; vascular compromise of the ophthalmic artery, retinal artery, or choroidal vessels; headache No. of Procedures 1 surgery  2–8 chemotherapy cycles every 3 weeks  2–8 treatments, every 4 weeks No. of EUAs 1 (unless patients are 
RB1+/-)  >20 for consolidation and monitoring  >10 since only 30% need consolidation  Patient survival >99%  >98%  high unless undetected high risk features High risk pathology detected Yes  No  No Hidden metastases treated No  Yes  No Identification of tumour genetics  Yes  No  No Duration of treatment 2 months (if not RB1+/-)  > 1 year  > 1 year Invasive surgery Loss of eye  1 central venous catheter  2–8 intracranial arterial canulations Long term toxicity Loss of eye  High tone hearing loss ~20% (Carboplatin); <1% AML (etoposide)  4% severe vascular choroidal toxicity; long term unknown vision risk psychological harms Possibly low self-esteem due to loss of the eye or artificial eye; distress of fitting and maintenance of artificial eye 
 Years of social isolation for treatments; delay physical, emotional, social development; long term separations of families; parental relationship breakdown; hospital-associated anxiety that hinders future medical care; post-traumatic stress disorder; Developmental Trauma Disorder; parental anxiety over illnesses; PTSD in parents or siblings; financial distress Radiation none  No Group78 D get EBRT; enucleation preferred  Fluoroscopy; No Group78 D to need EBRT Socio-economic impact108 minimal  profound  very profound Disease-specific mortality  <<1%  <1%  unknown Resource  Anaesthesia; ophthalmic surgery, ocularist; artificial eye  Anaesthesia; retinoblastoma and oncology expertise; drugs; laser and cryotherapy equipment; imaging equipment; Child Life support;181 long term follow-up 
 Anaesthesia; retinoblastoma-specific interventional radiology and oncology expertise; drugs; laser and cryotherapy equipment; imaging equipment; Child Life support;181 long term follow-up Long term follow-up Minimal unless inherited  Every 2–6 months for 4 years after tumour control  Every 2–6 months for 4 years after tumour control 
Availability:      Available in high income countries Yes  Yes  Yes Available in middle income countries Yes  Yes  Limited Available in low income countries Yes  No  No AML, acute myeloid leukaemia; EUA, examination under anaesthesia; IV, intravenous; IVC, intravenous chemotherapy; IAC, intra-arterial chemotherapy; * very wide range reflects different classifications and different follow-up durations.  
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